Chinese Oncology-Focused Innovative Drugs Developer Haihe Biopharma Nets $146M

Haihe Biopharma Co., a Chinese pharmaceutical company specialized in innovative oncology drugs, has secured a US$146.6 million new round of investment led by China-focused private equity firm Huagai Capital, said Haihe Biopharma in a statement released on Monday.

China Money Network

Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech

Register Now

Want to read this important story?

Access thousands of news articles and data posts over the past 9 years!

Already have an account or paid subscription? Log in

China Expert network